![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AstraZeneca’s Evusheld Wins UK Nod for Preventing COVID-19
AstraZeneca’s Evusheld Wins UK Nod for Preventing COVID-19
The UK’s Medicines and Healthcare products Regulatory Agency has approved AstraZeneca’s Evusheld (tixagevimab and cilgavimab) for the prevention of COVID-19, making it the first antibody combination cleared in the country for the indication.
The authorization was supported by results from a phase 3 study in 5,172 patients, which showed a 77 percent reduction in the risk of contracting symptomatic COVID-19 in those who received the drug compared with those given a placebo.
One dose of Evusheld confers protection for an estimated six months for immunocompromised individuals and others who are unlikely to mount an adequate response to COVID-19 vaccination, AstraZeneca said.
Evusheld received Emergency Use Authorization from the FDA in December 2021.
Upcoming Events
-
18Jul
-
21Oct